| __timestamp | Amgen Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 4699000000 | 54170000 |
| Thursday, January 1, 2015 | 4846000000 | 65378000 |
| Friday, January 1, 2016 | 5062000000 | 52263000 |
| Sunday, January 1, 2017 | 4870000000 | 35072000 |
| Monday, January 1, 2018 | 5332000000 | 27415000 |
| Tuesday, January 1, 2019 | 5150000000 | 36983000 |
| Wednesday, January 1, 2020 | 5730000000 | 50918000 |
| Friday, January 1, 2021 | 5368000000 | 63586000 |
| Saturday, January 1, 2022 | 5414000000 | 57967000 |
| Sunday, January 1, 2023 | 6179000000 | 53107000 |
| Monday, January 1, 2024 | 7096000000 | 23626000 |
In pursuit of knowledge
In the dynamic world of biotechnology, understanding the financial health of companies is crucial. This chart offers a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of two industry players: Amgen Inc. and Mesoblast Limited, from 2014 to 2023.
Amgen, a giant in the biotech sector, consistently reported SG&A expenses that were over 100 times greater than those of Mesoblast, highlighting its expansive operational scale. Notably, Amgen's expenses peaked in 2023, showing a 31% increase from 2014. In contrast, Mesoblast's expenses fluctuated, with a notable dip in 2018, reflecting its strategic shifts and market challenges.
This comparison underscores the diverse strategies and market positions of these companies, offering investors and analysts a deeper understanding of their operational dynamics.
Who Optimizes SG&A Costs Better? Amgen Inc. or Walgreens Boots Alliance, Inc.
Comparing SG&A Expenses: Amgen Inc. vs TG Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Amgen Inc. vs Viking Therapeutics, Inc.
Breaking Down SG&A Expenses: Amgen Inc. vs Merus N.V.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Sanofi and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Mesoblast Limited
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Mesoblast Limited vs Evotec SE: SG&A Expense Trends